Who are CXA-201 and metronidazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cxa-201-and-metronidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CXA-201 and metronidazole — Competitive Intelligence Brief

CXA-201 and metronidazole (CXA-201 and metronidazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic (CXA-201) combined with nitroimidazole antibiotic (metronidazole). Area: Infectious Disease.

phase 3 Rifamycin antibiotic (CXA-201) combined with nitroimidazole antibiotic (metronidazole) Bacterial RNA polymerase (CXA-201); DNA/RNA synthesis in anaerobic organisms (metronidazole) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

CXA-201 and metronidazole (CXA-201 and metronidazole) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). CXA-201 is a non-absorbed topical antibiotic that works synergistically with metronidazole to treat bacterial infections, particularly in the gastrointestinal tract or as a topical agent.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CXA-201 and metronidazole TARGET	CXA-201 and metronidazole	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Rifamycin antibiotic (CXA-201) combined with nitroimidazole antibiotic (metronidazole)	Bacterial RNA polymerase (CXA-201); DNA/RNA synthesis in anaerobic organisms (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic (CXA-201) combined with nitroimidazole antibiotic (metronidazole) class)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CXA-201 and metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/cxa-201-and-metronidazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab